Altace ANDAs On Hold Till June; Colbalt Gets Exclusivity, Not “Parking” Ticket
Executive Summary
Lupin Pharmaceuticals and five other pharma companies will have to wait at least until June to market their versions of ramipril capsules (King's Altace), as FDA ruled that Cobalt Pharmaceuticals is entitled to the 180-day generic drug exclusivity it was granted in 2005